signup3m



Cornerstone Therapeutics (NASDAQ:CRTX) announced findings from a study comparing all-cause, in-hospital mortality in more than 14,000 preterm infants with respiratory distress syndrome (RDS). The retrospective study evaluated Cornerstone's CUROSURF® (poractant alfa) compared to Infasurf® (calfactant) and Survanta® (beractant). Overall, CUROSURF treatment for RDS was associated with a significantly reduced likelihood of death compared to Infasurf, and a trend toward reduced mortality when compared with Survanta. The findings were published in the September 1, 2011 online issue of the Journal of Perinatology.

Read full article and discliamer at: http://crwewallstreet.com/?p=21365
Cornerstone Therapeutics (NASDAQ:CRTX) announced findings from a study comparing all-cause, in-hospital mortality in more than 14,000 preterm infants with respiratory distress syndrome (RDS). The retrospective study evaluated Cornerstone's CUROSURF® (poractant alfa) compared to Infasurf® (calfactant) and Survanta® (beractant). Overall, CUROSURF treatment for RDS was associated with a significantly reduced likelihood of death compared to Infasurf, and a trend toward reduced mortality when compared with Survanta. The findings were published in the September 1, 2011 online issue of the Journal of Perinatology. Read more at: http://crwewallstreet.com/?p=21365 z